Chih Kuang Chen

TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan.

The Medical & Pharmaceutical Industry Tech & Dev Center is a research and development center that focuses on improving the efficacy of fatty liver health products using local plants such as quinoa. The center is based in New Taipei, Taiwan and offers services such as medical equipment R&D, technical services, inspection, technology transfer, and talent training. The Taiwanese company has also developed technologies for immunological regulatory precision intermediate conditioning process and nervous repair functional merit cell cultivation process. The company also conducts public auctions for scrap equipment and promote integrity management and partner collaborations.

TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services.